EA201790867A1 - Способы и композиции для лечения субъекта антисмысловым олигонуклеотидом smad7 - Google Patents
Способы и композиции для лечения субъекта антисмысловым олигонуклеотидом smad7Info
- Publication number
- EA201790867A1 EA201790867A1 EA201790867A EA201790867A EA201790867A1 EA 201790867 A1 EA201790867 A1 EA 201790867A1 EA 201790867 A EA201790867 A EA 201790867A EA 201790867 A EA201790867 A EA 201790867A EA 201790867 A1 EA201790867 A1 EA 201790867A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- smad7
- treatment
- methods
- smell
- oligonucleotide
- Prior art date
Links
- 101700026522 SMAD7 Proteins 0.000 title abstract 4
- 102000049873 Smad7 Human genes 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108020004999 messenger RNA Proteins 0.000 abstract 2
- 239000002773 nucleotide Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- 102000054765 polymorphisms of proteins Human genes 0.000 abstract 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 239000000074 antisense oligonucleotide Substances 0.000 abstract 1
- 238000012230 antisense oligonucleotides Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462065598P | 2014-10-17 | 2014-10-17 | |
| PCT/EP2015/074066 WO2016059239A1 (en) | 2014-10-17 | 2015-10-16 | Methods and compositions for treating a subject with a smad7 antisense oligonucleotide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201790867A1 true EA201790867A1 (ru) | 2017-08-31 |
Family
ID=54330761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201790867A EA201790867A1 (ru) | 2014-10-17 | 2015-10-16 | Способы и композиции для лечения субъекта антисмысловым олигонуклеотидом smad7 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10337004B2 (enExample) |
| EP (1) | EP3207136A1 (enExample) |
| JP (1) | JP2017532961A (enExample) |
| KR (1) | KR20170069262A (enExample) |
| CN (1) | CN107406851A (enExample) |
| AU (1) | AU2015332624A1 (enExample) |
| CA (1) | CA2964667A1 (enExample) |
| EA (1) | EA201790867A1 (enExample) |
| IL (1) | IL251717A0 (enExample) |
| MA (1) | MA43331A (enExample) |
| MX (1) | MX2017004973A (enExample) |
| WO (1) | WO2016059239A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| NZ592673A (en) | 2008-11-13 | 2013-01-25 | Giuliani Int Ltd | Antisense compositions with enteric coating for treating crohn's disease, colitis and bowel disease |
| AU2012307336B2 (en) | 2011-09-15 | 2017-08-24 | Nogra Pharma Limited | Methods for monitoring responsiveness to anti-SMAD7 therapy |
| CA2870547A1 (en) | 2012-04-18 | 2013-10-24 | Nogra Pharma Limited | Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation |
| US10006029B2 (en) | 2013-03-15 | 2018-06-26 | Nogra Pharma Limited | Methods of treating colorectal cancer |
| MA39963A (fr) | 2014-05-09 | 2017-03-15 | Nogra Pharma Ltd | Méthodes de traitement d'une maladie inflammatoire chronique de l'intestin |
| JP2017537973A (ja) * | 2014-10-17 | 2017-12-21 | ノグラ ファーマ リミテッド | バイオマーカーレベルを使用してｓｍａｄ７アンチセンスオリゴヌクレオチドを投与するおよびモニタリングするための方法 |
| JP2017532961A (ja) | 2014-10-17 | 2017-11-09 | ノグラ ファーマ リミテッド | Ｓｍａｄ７アンチセンスオリゴヌクレオチドによる対象を処置するための方法および組成物 |
| EP3420082A4 (en) * | 2016-02-23 | 2019-10-16 | Celgene Alpine Investment Company II, LLC | METHOD FOR THE TREATMENT OF DARM FIBROSIS USING SMAD7 INHIBITION |
| EP3562943A1 (en) * | 2016-12-30 | 2019-11-06 | Nogra Pharma Limited | Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis |
| MX2022013261A (es) * | 2020-04-24 | 2022-11-14 | Nogra Pharma Ltd | Composiciones de oligonucleotidos antisentido (aso) contra smad7 y metodos para usar las mismas. |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1456380T1 (sl) | 2001-11-02 | 2012-11-30 | Giuliani Int Ltd | Smad inhibitorji za zdravljenje cns bolezni |
| ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| NZ592673A (en) | 2008-11-13 | 2013-01-25 | Giuliani Int Ltd | Antisense compositions with enteric coating for treating crohn's disease, colitis and bowel disease |
| WO2010085151A2 (en) * | 2009-01-26 | 2010-07-29 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Means and methods for modulating notch3 protein expression and/or the coding region of notch3; compositions and use thereof in the treatment of cadasil |
| AU2011213563B2 (en) * | 2010-02-08 | 2015-12-24 | Ionis Pharmaceuticals, Inc. | Selective reduction of allelic variants |
| AU2012307336B2 (en) | 2011-09-15 | 2017-08-24 | Nogra Pharma Limited | Methods for monitoring responsiveness to anti-SMAD7 therapy |
| CA2870547A1 (en) | 2012-04-18 | 2013-10-24 | Nogra Pharma Limited | Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation |
| US10006029B2 (en) | 2013-03-15 | 2018-06-26 | Nogra Pharma Limited | Methods of treating colorectal cancer |
| WO2014140333A1 (en) | 2013-03-15 | 2014-09-18 | Nogra Pharma Limited | Methods of treating colorectal cancer |
| MA39963A (fr) * | 2014-05-09 | 2017-03-15 | Nogra Pharma Ltd | Méthodes de traitement d'une maladie inflammatoire chronique de l'intestin |
| EP3207135A2 (en) | 2014-10-17 | 2017-08-23 | Celgene Alpine Investment Company II, LLC | Isotopologues of smad7 antisense oligonucleotides |
| JP2017532961A (ja) | 2014-10-17 | 2017-11-09 | ノグラ ファーマ リミテッド | Ｓｍａｄ７アンチセンスオリゴヌクレオチドによる対象を処置するための方法および組成物 |
| JP2017537973A (ja) | 2014-10-17 | 2017-12-21 | ノグラ ファーマ リミテッド | バイオマーカーレベルを使用してｓｍａｄ７アンチセンスオリゴヌクレオチドを投与するおよびモニタリングするための方法 |
| MA41271A (fr) | 2014-12-26 | 2017-10-31 | Celgene Alpine Invest Company Ii Llc | Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7 |
| JP2018531936A (ja) | 2015-09-30 | 2018-11-01 | ノグラ ファーマ リミテッド | バイオマーカー発現に基づいてｓｍａｄ７アンチセンスオリゴヌクレオチドを使用する方法 |
| US20180289692A1 (en) | 2015-09-30 | 2018-10-11 | Celgene Corporation | Tlr modulators and methods of use |
-
2015
- 2015-10-16 JP JP2017520449A patent/JP2017532961A/ja active Pending
- 2015-10-16 MX MX2017004973A patent/MX2017004973A/es unknown
- 2015-10-16 US US15/519,468 patent/US10337004B2/en not_active Expired - Fee Related
- 2015-10-16 CA CA2964667A patent/CA2964667A1/en not_active Abandoned
- 2015-10-16 EA EA201790867A patent/EA201790867A1/ru unknown
- 2015-10-16 MA MA043331A patent/MA43331A/fr unknown
- 2015-10-16 AU AU2015332624A patent/AU2015332624A1/en not_active Abandoned
- 2015-10-16 CN CN201580069041.9A patent/CN107406851A/zh active Pending
- 2015-10-16 WO PCT/EP2015/074066 patent/WO2016059239A1/en not_active Ceased
- 2015-10-16 EP EP15781642.2A patent/EP3207136A1/en not_active Withdrawn
- 2015-10-16 KR KR1020177012839A patent/KR20170069262A/ko not_active Withdrawn
-
2017
- 2017-04-13 IL IL251717A patent/IL251717A0/en unknown
-
2019
- 2019-05-21 US US16/418,108 patent/US20190338283A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2017004973A (es) | 2017-12-07 |
| IL251717A0 (en) | 2017-06-29 |
| AU2015332624A1 (en) | 2017-05-04 |
| KR20170069262A (ko) | 2017-06-20 |
| MA43331A (fr) | 2017-08-23 |
| EP3207136A1 (en) | 2017-08-23 |
| CA2964667A1 (en) | 2016-04-21 |
| US20190338283A1 (en) | 2019-11-07 |
| CN107406851A (zh) | 2017-11-28 |
| US10337004B2 (en) | 2019-07-02 |
| US20170240893A1 (en) | 2017-08-24 |
| JP2017532961A (ja) | 2017-11-09 |
| WO2016059239A1 (en) | 2016-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201790867A1 (ru) | Способы и композиции для лечения субъекта антисмысловым олигонуклеотидом smad7 | |
| EA201692537A1 (ru) | Замещенные нуклеозиды, нуклеотиды и их аналоги | |
| MX2017008183A (es) | Nucleosidos sustituidos, nucleotidos y analogos de estos. | |
| EA201690526A1 (ru) | Замещенные нуклеозиды, нуклеотиды и их аналоги | |
| MX2017008184A (es) | Nucleosidos sustituidos, nucleotidos y analogos de estos. | |
| PH12017500669A1 (en) | Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression | |
| CY1121037T1 (el) | Αντινοηματικα πολυνουκλεοτιδια για να διεγειρεται παραλειψη εξονιου και μεθοδοι θεραπειας δυστροφιων | |
| EA201692370A1 (ru) | КОМПОЗИЦИИ иРНК АНГИОТЕНЗИНОГЕНА (AGT) И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ | |
| SA519401379B1 (ar) | علاج فيروس مرتبط بغدة لمرض هنتنجتون | |
| PH12016502564A1 (en) | Substituted nucleosides, nucleosides and analogs thereof | |
| WO2016106401A3 (en) | Rna agents for p21 gene modulation | |
| EA201591707A1 (ru) | КОМПОЗИЦИИ иРНК КОМПОНЕНТА КОМПЛЕМЕНТА C5 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| PH12015501423A1 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| EP3685819C0 (en) | Solid anhydrous cosmetic composition, preparation process, cosmetic treatment processes and associated kit | |
| NZ730296A (en) | Modified double-stranded rna agents | |
| DK3265102T3 (da) | Beta-d-2'-deoxy-2'alpha-fluoro-2'-beta-c-substituerede-2-modificerede-n6-substituerede purinnukleotider til hcv-behandling | |
| EA201790802A1 (ru) | Соединения против tnf | |
| PL3512863T3 (pl) | 2'-Podstawione-N6-podstawione nukleotydy purynowe do leczenia zakażeń wirusem RNA | |
| MX388737B (es) | Oligonucleótidos terapéuticos. | |
| WO2017007886A3 (en) | Compositions for inhibiting dux4 gene expression and uses thereof | |
| EA201791471A1 (ru) | Способы применения антисмысловых олигонуклеотидов smad7 | |
| NZ741841A (en) | Antisense oligonucleotides for use in treating alzheimer’s disease | |
| MA44836A (fr) | Procédés de traitement du syndrome polykystique des reins | |
| EP3307326A4 (en) | METHOD FOR TREATING LEPTOMENINGEAL CARCINOMATOSIS | |
| AR132165A2 (es) | Composiciones y métodos para la inhibición de la expresión génica de hao1 (hidroxiácido oxidasa 1 (glicolato oxidasa)) |